Try the modernized beta website. Learn more about the modernization effort.
Working… Menu

Dexmedetomidine in the Treatment of Agitation Associated With Bipolar Disorder (SERENITY II)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT04276883
Recruitment Status : Completed
First Posted : February 19, 2020
Last Update Posted : August 19, 2020
Cognitive Research Corporation
Information provided by (Responsible Party):
BioXcel Therapeutics Inc

No Study Results Posted on for this Study
Recruitment Status : Completed
Actual Primary Completion Date : May 21, 2020
Actual Study Completion Date : May 21, 2020